



**Nurtec<sup>®</sup> ODT**  
(rimegepant)  
orally disintegrating tablets 75 mg

## Help your patients access Nurtec ODT

The only migraine medication approved  
to treat and prevent all in one.<sup>1,2</sup>



See commercial formulary coverage in your area



***“Yesss! I love Nurtec ODT. So glad my insurance covers a treatment for my migraine pain!!!!”***

**Vanessa M.**

Actual Nurtec ODT patient since 2021.  
Individual results may vary.

Patients were invited to share their treatment experience.

**INDICATIONS**

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

**SELECT IMPORTANT SAFETY INFORMATION**

**Contraindications:** Hypersensitivity to Nurtec ODT or any of its components.

Please see full Important Safety Information on the last page and click here for full [Prescribing Information](#).

# How to prescribe Nurtec ODT to meet your patients' individual needs each month<sup>1</sup>

## Coverage for 96% of commercially-insured lives\*



quick assistance for you and your patients from our dedicated call center: 1-833-4NURTEC



for Prior Authorization assistance<sup>†</sup>  
www.covermymeds.com  
or 1-866-452-5017

\*Managed Markets Insight & Technology LLC since 1/10/23. <sup>†</sup>CoverMyMeds is an independent third party.

## NURTEC ODT COMMERCIAL COVERAGE / NATIONAL PLANS

PHARMACY BENEFIT MANAGER	ACUTE	ACUTE QL	PREVENTIVE	PREVENTIVE QL
CVS	Preferred	16	Preferred	16
ANTHEM	Preferred	8	Preferred	18
AETNA	Preferred	16	Preferred	16
EXPRESS SCRIPTS	Covered	15	Covered	15
CIGNA	Preferred	16	Preferred	16
OPTUM Rx	Preferred	8	Preferred	16
UNITEDHEALTHCARE	Preferred	8	Preferred	16

QL=quantity limit

**For more information reach out to your Sales Representative or visit [nurtec-hcp.com](http://nurtec-hcp.com) to search formulary coverage.**

### SELECT IMPORTANT SAFETY INFORMATION

**Warnings and Precautions:** If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

**Please see full Important Safety Information on the last page and click here for full [Prescribing Information](#).**

## How to prescribe Nurtec ODT (rimegepant) 75 mg

### 1 In your EMR, simply select:

**A**

**ASPN Pharmacies, LLC**  
290 West Mount Pleasant Ave,  
Livingston, NJ 07039  
NPI: 1538590690  
Prescriptions can also be faxed to  
**ASPN Pharmacies** at 1-877-371-2213.

or

**B**

**Your local pharmacy**  
(for prescriptions not serviced  
through Nurtec<sup>®</sup> OneSource)

#### Don't see ASPN Pharmacies in your ePrescribe platform?

Select **ASPN Pharmacies** in your EMR mail-order pharmacy option or check with your IT support for the last system update. If additional assistance is needed, please contact your EMR provider. For Nurtec<sup>®</sup> OneSource issues, call 1-833-4NURTEC and select option 2.

### 2 Select ICD-10-CM code:

Four common ICD-10 codes are listed below.<sup>‡</sup> For additional applicable codes, please refer to an ICD-10-CM resource.

#### ICD-10-CM code & description

G43,  
Migraine

G43.0, Migraine  
without aura

G43.1, Migraine  
with aura

G43.9, Migraine,  
unspecified

<sup>‡</sup>Codes are provided for informational purposes only. List may not be comprehensive. The healthcare provider is responsible for determining appropriate coding for treatment of their patients. Codes are not intended to encourage or suggest a use that is inconsistent with FDA-approved uses.

### 3 Select quantity:

**A**

**1 blister pack, 8 tablets**  
NDC: 72618-3000-02

or

**B**

**2 blister packs, 16 tablets**  
NDC: 72618-3000-02

SIG: Take one tablet by mouth as needed (PRN) for ACUTE treatment or one every other day (EOD) for PREVENTIVE treatment. No more than one dose in 24 hours.



**Contact a Support Specialist:** For questions, please call 1-833-4NURTEC (1-833-468-7832).

#### SELECT IMPORTANT SAFETY INFORMATION

**Adverse Reactions:** The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Please see full Important Safety Information on the last page and click here for full [Prescribing Information](#).

**THE ONLY MIGRAINE MEDICATION THAT**

**TREATS & PREVENTS**

**ALL IN ONE<sup>1,2</sup>**

**INDICATIONS**

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

**IMPORTANT SAFETY INFORMATION**

**Contraindications:** Hypersensitivity to Nurtec ODT or any of its components.

**Warnings and Precautions:** If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

**Adverse Reactions:** The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

**Drug Interactions:** Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp.

**Use in Specific Populations:** *Pregnancy:* It is not known if Nurtec ODT can harm an unborn baby. *Lactation:* The transfer of rimegepant into breastmilk is low (<1%). *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

**Please click here for full Prescribing information.**

**Price disclosure information for prescribers is available [here](#).**

**References:** **1.** Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. **2.** Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. *Lancet*. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7

